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Background
Poxvirus viruses have been utilized for many years as vac-
cine vectors. Recent years have seen an increase in efforts
to identify safer pox vectors to express heterologous anti-
gens, in this case HIV antigens.
Safer pox vectors have included MVA, ALVAC and NYVAC,
which are all replication deficient in human cells. How-
ever, the loss of replication competence has also reduced
antigen expression, and therefore, immunologic response
to the vaccination. We have constructed vectors in a
NYVAC background that are replication competent but
attenuated for virulence.
Methods
To restore replication competence in NYVAC that
expresses clade C HIV gag, pol, nef and env (NYVAC-C),
we inserted genes deleted in the parental vector: 1)
NYVAC-C-KC includes the human host range genes K1L
and C7L; 2) NYVAC-C+12 includes the entire cassette of
genes from K1L to C7L that is deleted from NYVAC.
To decrease virulence, we deleted the E3L gene, which is
required for interferon-resistance and virulence, and
replaced it with a gene from Ambystoma tigrinum virus
(ATV, the new virus is NYVAC-C+12-ATV), which restores
a single round of replication.
Results
In vitro characterization of the constructs demonstrates
restoration of replication in primary and human cell lines.
NYVAC-C+12-ATV leads to induction of pro-inflamma-
tory signal transduction pathways. Pathogenicity studies
in newborn mice demonstrate attenuation of 3–5 logs
when compared to wt vaccinia virus or to NYCBH.
Conclusion
NYVAC constructs provide increased safety in the most
sensitive of animal models. Because antigen expression is
increased in these replication-competent constructs, they
may be more immunogenic than replication-defective
poxvirus vectors. Increased pro-inflammatory signal
transduction in cells infected with NYVAC-C+12-ATV may
also lead to an increase in immunogenicity of this highly
attenuated vector. Thus, these replication competent,
attenuated viral vectors may have improved immuno-
genicity over replication defective poxvirus vectors, while
maintaining an improved safety profile.
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